Pernicious Anemia

This presentation provides an in-depth overview of Pernicious Anemia (PA)—a chronic autoimmune condition that results in impaired absorption of vitamin B12 due to intrinsic factor deficiency, leading to megaloblastic anemia and systemic complications. It explores the epidemiology, genetic predispositions, and immunopathogenesis, focusing on autoimmune gastritis, parietal cell and intrinsic factor antibodies, and their role in vitamin B12 malabsorption. Clinical manifestations such as fatigue, pallor, glossitis, neuropathy, cognitive impairment, and increased gastric cancer risk are discussed in detail.

Diagnostic approaches include complete blood counts, serum vitamin B12 and methylmalonic acid levels, antibody testing, and gastric biopsy when indicated. Conventional management relies on lifelong vitamin B12 supplementation (parenteral or high-dose oral), but challenges remain in addressing neurological sequelae and long-term monitoring. Beyond established therapy, this presentation highlights emerging regenerative and integrative innovations, including Precursor Stem Cell Therapy (PSCT), Autologous Active Specific Immunotherapy (AASI®), Nano Organo Peptides (NOP) Thymus and Mito Organelle (MO) Thymus for Thymus Therapy, Nano Organo Peptides (NOP) Super Transfer Factor (STF), Mito Organelles (MO) Super Transfer Factor (STF), and GcMAF Forte. Supported by clinical references and case-based insights, this program is tailored for hematologists, gastroenterologists, neurologists, and healthcare professionals seeking to advance their understanding of PA and explore novel therapeutic frontiers.